HOT Study shows reduced risk of heart attacks in women, and good blood pressure control in older patients, on felodipine ER (Plendil) - based therapy
New data from the HOT (Hypertension Optimal Treatment) Study published in the May issue of the Journal of Hypertension,1 show that women with hypertension achieve target blood pressures more easily than men and experience greater benefits from antihypertensive treatment. The data also show that older people achieved a 1-2 mm Hg lower blood pressure, had fewer adverse events and more frequently reached blood pressure targets than younger patients. The findings have important implications for approaches to hypertension management.
Unlike many cardiovascular studies, the HOT Study,2 the largest intervention study in hypertension ever completed, involved a large number of women and older people. Nearly half of the 18,790 people studied were women, and one-third were over 65 years old. The study was conducted in 26 countries. Patients were followed for an average of 3.8 years. Blood pressure reduction was achieved with a regimen of the calcium antagonist felodipine ER (Plendil) plus an ACE inhibitor or beta blocker if required to meet blood pressure targets of < 90 mm Hg, < 85 mm Hg, or < 80 mm Hg. In addition patients were randomised to acetylsalicylic acid (ASA) 75mg daily or placebo.
The results of the age and gender differences in the response to the HOT Study blood pressure targets provide firm evidence for generally adopting an intensive approach to the treatment of hypertension in all patients. The findings provide robust evidence that the World Health Organization-International Society of Hypertension (WHO-ISH) targets of an optimal or normal blood pressure of 130/85 mm Hg in young and middle-aged hypertensives, and a target below 140/90 mm Hg3 for the elderly, can be achieved. The treatment regimen was well tolerated. Peripheral oedema was the most frequent adverse event and
'"/>
Contact: Jonathan Wilson
jonathan.wilson@ketchumcomms.co.uk
44-207-379-3234
Ketchum
8-May-2000